New real-world data show high rate of patient adherence to Tepezza for thyroid eye disease (TED) – Horizon Therapeutics
Horizon Therapeutics plc announced findings of a real-world adherence analysis of Tepezza for the treatment of TED ( Thyroid Eye Disease) at the American Academy of Ophthalmology Annual Meeting (AAO 2021). Tepezza is the first and only medicine approved by the FDA for the treatment of TED – a serious, progressive and potentially vision-threatening rare autoimmune disease. The analysis found […]
Recent Comments